AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life...more
Arnall Golden Gregory LLP's Food and Drug Newsletter is a monthly update of legal and regulatory issues that affect the FDA-regulated community and highlights articles from members of AGG outside the Food and Drug practice....more
While life sciences M&A activity soared to a new high in 2019, the uncertainty surrounding the pandemic has led to a slow down in deal making activity. However, as the crisis in the U.S. subsides and the U.S. economy...more
Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios.
Register now for this one-hour,...more
9/27/2019
/ Business Development ,
Business Ownership ,
Capital Raising ,
Continuing Legal Education ,
Debt Financing ,
Emerging Growth Companies ,
Exit Strategies ,
Initial Public Offering (IPO) ,
Investment Management ,
Investors ,
Life Sciences ,
Private Equity ,
Publicly-Traded Companies ,
Regulatory Requirements ,
Securities Transactions ,
Seed Financing ,
Startups ,
Venture Capital ,
Webinars